previously several years, the UK has witnessed a revolution in medical fat‑loss therapies — within the introduction of semaglutide (Wegovy®) to the expanding acceptance of tirzepatide (Mounjaro®). Now, A different identify is drawing consideration in both clinical and general public wellbeing cir